Advancing the Peptide Pipeline - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Advancing the Peptide Pipeline
The pharmaceutical majors build their capabilities in peptide technology, and contract manufacturers expand to meet growing demand for bulk peptides.

Pharmaceutical Technology

PolyPeptide Laboratories. PolyPeptide Laboratories (Torrance, CA) is building a new peptide plant in Ambernath, India, which is scheduled to be operational in 2008. Last year, it increased its peptide manufacturing capacity in Torrance, California; Malmo, Sweden; and Hillerod, Denmark. These expansions increased solid-phase peptide synthesis capacity, complementing its large-scale, solution-phase synthesis capabilities in Malmo and Hillerod. The company also expanded its preGMP development capabilities in the United States.

NeoMPS. NeoMPS (Strasbourg, France) is planning to invest EUR10 million ($13.6 million) to expand peptide capacity at its facility in Strasbourg, France, with completion scheduled for mid-2008. The investment more than triples the company's large-scale manufacturing capacities (solid and liquid phases) in Strasbourg. The company has multi kilogram-scale CGMP peptide capacity at its facilities in Strasbourg and San Diego.

Bachem. Bachem (Bubendorf, Switzerland) invested $10 million to expand production capacity by 40% for the CGMP manufacture of peptide active ingredients at its facilities in Torrance, California. The company added a new production unit for solid-phase peptide synthesis and purification that become operational in July 2006.

Almac Sciences. Last year Almac Sciences (Craigavon, Northern Ireland) commissioned a 500,000 ($993,000) package of new assets at its facilities in Northern Ireland and Scotland. New investment at its large-scale, multi-product site at Craigavon, Northern Ireland included automated peptide synthesis equipment, a freeze-drying suite, and preparative high-performance liquid chromatography. New equipment for small-scale peptide synthesis was added to its production and research and development center in Edinburgh. Almac specializes in long-chain peptides and has developed synthesis and purification techniques to make peptides up to 170 amino acids in length.

Lonza. In 2006, Lonza acquired UCB Bioproducts and its peptide manufacturing facility in Braine-l'Alleud, Belgium and completed its integration into Lonza in December 2006. The facility has manufactured over 400 preclinical and clinical peptide drug candidates, estimates Lonza. Examples of generic peptide APIs manufactured at the Braine facility include somatostatin and desmopressin.

Genzyme Pharmaceuticals. Genzyme Pharmaceuticals (Cambridge, MA), a contract peptide manufacturer, is partnered with Brookwood Pharmaceuticals, Inc. (Birmingham, Alabama) to offer customized solutions for parenteral formulations by combining expertise in peptide delivery and synthesis. The companies formed a pact last year.


1. J. Lakshmikanthan, "Outsouricng: Biologics: The CMO Advantage," BioPharm Intl. 20 (2) 40–48 (2007).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here